Dietary modulation of markers of inflammation and oxidation as risk factors of chronic, degenerative diseases ... annual report |
Pubbl/distr/stampa | [Washington, D.C.], : U.S. Dept. of Agriculture, Agricultural Research Service |
Descrizione fisica | : HTML files |
Disciplina | 616 |
Soggetto topico |
Phytochemicals - Therapeutic use - United States
Polyphenols - Therapeutic use - United States Inflammation - Diet therapy - United States Oxidative stress - Diet therapy - United States Degeneration (Pathology) - Diet therapy - United States Phytochemicals - Therapeutic use |
Soggetto genere / forma | Periodicals. |
ISSN | 1947-072X |
Formato | Materiale a stampa |
Livello bibliografico | Periodico |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910698686703321 |
[Washington, D.C.], : U.S. Dept. of Agriculture, Agricultural Research Service | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Mechanism of the anticancer effect of phytochemicals / / edited by S. Zahra Bathaie, Department of Clinical Biochemistry, Tarbiat Modares University Tehran, Iran, Fuyuhiko Tamanoi, Department of Microbiology, Immunology and Molecular Genetics Jonsson Comprehensive Cancer Center Molecular Biology Institue University of California Los Angeles, California, USA |
Edizione | [First edition.] |
Pubbl/distr/stampa | Waltham, MA : , : Elsevier Science, , 2015 |
Descrizione fisica | 1 online resource (285 p.) |
Disciplina | 616.994061 |
Collana | Enzymes |
Soggetto topico |
Cancer - Chemoprevention
Cancer - Diet therapy Phytochemicals - Therapeutic use |
Soggetto genere / forma | Electronic books. |
ISBN |
0-12-803877-2
0-12-803876-4 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Front Cover; Mechanism of the Anticancer Effect of Phytochemicals; Copyright; Contents; Contributors; Preface; Chapter One: How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth?; 1. Introduction; 2. Phytochemicals Application in Chemoprevention Strategies; 2.1. Blocking Initiation/Reversing Promotion; 2.2. Activating Phase II Detoxifying Enzymes; 2.3. Prooxidant/Antioxidant Activities; 2.4. Protection Against Radiation; 2.5. Alteration in Signaling Pathways; 2.6. Effect on Cell-Cell Adhesion Machinery; 2.7. Induction of Epigenetic Changes
3. Phytochemicals Usage as Chemotherapeutic3.1. Inhibition of Enzymes; 3.1.1. Inhibition of Topoisomerases I or II; 3.1.2. Effect on Telomerase; 3.1.3. Other Enzymes; 3.2. Direct Binding to Biomacromolecules; 3.3. Epigenetic Alteration/Chromatin Modification; 3.3.1. Histone Modifications: Acetylation/Deacetylation and Methylation/Demethylation; 3.3.2. DNA Methylation Status; 3.4. RNA Modulation; 3.5. Autophagy and UPR68; 3.6. Apoptosis Induction; 3.7. Cell Cycle Arrest; 3.8. Inhibiting Angiogenesis; 3.9. Adjuvant/Combinatorial Therapy; 4. Summary; References Chapter Two: Quercetin and Tryptanthrin: Two Broad Spectrum Anticancer Agents for Future Chemotherapeutic Interventions1. Introduction; 2. Quercetin; 2.1. Source; 2.2. Biosynthesis; 2.3. Structure and Antioxidative Property; 2.4. Properties; 2.4.1. Antioxidant Property; 2.4.2. Free Radical Scavenging Activity; 2.4.3. Nitric Oxide Inhibitory Action; 2.4.4. Inhibition of Xanthine Oxidase; 2.4.5. Interaction with Other Enzyme Systems; 2.5. Pharmacokinetics; 2.6. Role as an Anticancer Agent; 2.6.1. Cell Cycle Regulation; 2.6.2. Quercetinś Effect on Apoptosis 2.6.3. Inhibition of Pathways Involved in Tumor Growth and Invasiveness2.7. Quercetinś Role as an Anti-Inflammatory Agent; 2.8. Quercetinś Influence on p53; 2.9. Quercetinś Nontoxicity Against Normal Cells; 2.10. Quercetinś Action Against Chemical-Induced Tumor and Xenograft; 2.11. Synergism with Other Drugs; 2.12. Clinical Study; 3. Tryptanthrin; 3.1. Chemistry; 3.2. Source; 3.3. Medicinal Value; 3.4. Cytotoxic and Anticancer Properties of Tryptanthrin; 3.5. Structural Modification of Tryptanthrin for Increasing its Bioactivity 3.6. Tryptanthrin Prevents Development of Cancer by the Inhibition of Various Molecular Events3.6.1. Antioxidant Activity; 3.6.2. Anti-Inflammatory Activity; 3.7. Angiogenesis; 3.8. Toxicological Analysis; 4. Conclusion; Acknowledgement; References; Chapter Three: Potential Anticancer Properties and Mechanisms of Action of Withanolides; 1. Introduction; 2. Reactive Oxygen Species Signaling; 3. Cytoskeletal Organizing and Structural Proteins; 4. Proteasomal Inhibition; 5. Inhibition of Mitosis; 6. Transcription Factors; 7. Heat Shock Proteins; 8. Metabolic Enzymes; 9. Synergistic Action References |
Record Nr. | UNINA-9910461754703321 |
Waltham, MA : , : Elsevier Science, , 2015 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Mechanism of the anticancer effect of phytochemicals / / edited by S. Zahra Bathaie, Department of Clinical Biochemistry, Tarbiat Modares University Tehran, Iran, Fuyuhiko Tamanoi, Department of Microbiology, Immunology and Molecular Genetics Jonsson Comprehensive Cancer Center Molecular Biology Institue University of California Los Angeles, California, USA |
Edizione | [First edition.] |
Pubbl/distr/stampa | Waltham, MA : , : Elsevier Science, , 2015 |
Descrizione fisica | 1 online resource (285 p.) |
Disciplina | 616.994061 |
Collana | Enzymes |
Soggetto topico |
Cancer - Chemoprevention
Cancer - Diet therapy Phytochemicals - Therapeutic use |
ISBN |
0-12-803877-2
0-12-803876-4 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Front Cover; Mechanism of the Anticancer Effect of Phytochemicals; Copyright; Contents; Contributors; Preface; Chapter One: How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth?; 1. Introduction; 2. Phytochemicals Application in Chemoprevention Strategies; 2.1. Blocking Initiation/Reversing Promotion; 2.2. Activating Phase II Detoxifying Enzymes; 2.3. Prooxidant/Antioxidant Activities; 2.4. Protection Against Radiation; 2.5. Alteration in Signaling Pathways; 2.6. Effect on Cell-Cell Adhesion Machinery; 2.7. Induction of Epigenetic Changes
3. Phytochemicals Usage as Chemotherapeutic3.1. Inhibition of Enzymes; 3.1.1. Inhibition of Topoisomerases I or II; 3.1.2. Effect on Telomerase; 3.1.3. Other Enzymes; 3.2. Direct Binding to Biomacromolecules; 3.3. Epigenetic Alteration/Chromatin Modification; 3.3.1. Histone Modifications: Acetylation/Deacetylation and Methylation/Demethylation; 3.3.2. DNA Methylation Status; 3.4. RNA Modulation; 3.5. Autophagy and UPR68; 3.6. Apoptosis Induction; 3.7. Cell Cycle Arrest; 3.8. Inhibiting Angiogenesis; 3.9. Adjuvant/Combinatorial Therapy; 4. Summary; References Chapter Two: Quercetin and Tryptanthrin: Two Broad Spectrum Anticancer Agents for Future Chemotherapeutic Interventions1. Introduction; 2. Quercetin; 2.1. Source; 2.2. Biosynthesis; 2.3. Structure and Antioxidative Property; 2.4. Properties; 2.4.1. Antioxidant Property; 2.4.2. Free Radical Scavenging Activity; 2.4.3. Nitric Oxide Inhibitory Action; 2.4.4. Inhibition of Xanthine Oxidase; 2.4.5. Interaction with Other Enzyme Systems; 2.5. Pharmacokinetics; 2.6. Role as an Anticancer Agent; 2.6.1. Cell Cycle Regulation; 2.6.2. Quercetinś Effect on Apoptosis 2.6.3. Inhibition of Pathways Involved in Tumor Growth and Invasiveness2.7. Quercetinś Role as an Anti-Inflammatory Agent; 2.8. Quercetinś Influence on p53; 2.9. Quercetinś Nontoxicity Against Normal Cells; 2.10. Quercetinś Action Against Chemical-Induced Tumor and Xenograft; 2.11. Synergism with Other Drugs; 2.12. Clinical Study; 3. Tryptanthrin; 3.1. Chemistry; 3.2. Source; 3.3. Medicinal Value; 3.4. Cytotoxic and Anticancer Properties of Tryptanthrin; 3.5. Structural Modification of Tryptanthrin for Increasing its Bioactivity 3.6. Tryptanthrin Prevents Development of Cancer by the Inhibition of Various Molecular Events3.6.1. Antioxidant Activity; 3.6.2. Anti-Inflammatory Activity; 3.7. Angiogenesis; 3.8. Toxicological Analysis; 4. Conclusion; Acknowledgement; References; Chapter Three: Potential Anticancer Properties and Mechanisms of Action of Withanolides; 1. Introduction; 2. Reactive Oxygen Species Signaling; 3. Cytoskeletal Organizing and Structural Proteins; 4. Proteasomal Inhibition; 5. Inhibition of Mitosis; 6. Transcription Factors; 7. Heat Shock Proteins; 8. Metabolic Enzymes; 9. Synergistic Action References |
Record Nr. | UNINA-9910797589003321 |
Waltham, MA : , : Elsevier Science, , 2015 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Mechanism of the anticancer effect of phytochemicals / / edited by S. Zahra Bathaie, Department of Clinical Biochemistry, Tarbiat Modares University Tehran, Iran, Fuyuhiko Tamanoi, Department of Microbiology, Immunology and Molecular Genetics Jonsson Comprehensive Cancer Center Molecular Biology Institue University of California Los Angeles, California, USA |
Edizione | [First edition.] |
Pubbl/distr/stampa | Waltham, MA : , : Elsevier Science, , 2015 |
Descrizione fisica | 1 online resource (285 p.) |
Disciplina | 616.994061 |
Collana | Enzymes |
Soggetto topico |
Cancer - Chemoprevention
Cancer - Diet therapy Phytochemicals - Therapeutic use |
ISBN |
0-12-803877-2
0-12-803876-4 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Front Cover; Mechanism of the Anticancer Effect of Phytochemicals; Copyright; Contents; Contributors; Preface; Chapter One: How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth?; 1. Introduction; 2. Phytochemicals Application in Chemoprevention Strategies; 2.1. Blocking Initiation/Reversing Promotion; 2.2. Activating Phase II Detoxifying Enzymes; 2.3. Prooxidant/Antioxidant Activities; 2.4. Protection Against Radiation; 2.5. Alteration in Signaling Pathways; 2.6. Effect on Cell-Cell Adhesion Machinery; 2.7. Induction of Epigenetic Changes
3. Phytochemicals Usage as Chemotherapeutic3.1. Inhibition of Enzymes; 3.1.1. Inhibition of Topoisomerases I or II; 3.1.2. Effect on Telomerase; 3.1.3. Other Enzymes; 3.2. Direct Binding to Biomacromolecules; 3.3. Epigenetic Alteration/Chromatin Modification; 3.3.1. Histone Modifications: Acetylation/Deacetylation and Methylation/Demethylation; 3.3.2. DNA Methylation Status; 3.4. RNA Modulation; 3.5. Autophagy and UPR68; 3.6. Apoptosis Induction; 3.7. Cell Cycle Arrest; 3.8. Inhibiting Angiogenesis; 3.9. Adjuvant/Combinatorial Therapy; 4. Summary; References Chapter Two: Quercetin and Tryptanthrin: Two Broad Spectrum Anticancer Agents for Future Chemotherapeutic Interventions1. Introduction; 2. Quercetin; 2.1. Source; 2.2. Biosynthesis; 2.3. Structure and Antioxidative Property; 2.4. Properties; 2.4.1. Antioxidant Property; 2.4.2. Free Radical Scavenging Activity; 2.4.3. Nitric Oxide Inhibitory Action; 2.4.4. Inhibition of Xanthine Oxidase; 2.4.5. Interaction with Other Enzyme Systems; 2.5. Pharmacokinetics; 2.6. Role as an Anticancer Agent; 2.6.1. Cell Cycle Regulation; 2.6.2. Quercetinś Effect on Apoptosis 2.6.3. Inhibition of Pathways Involved in Tumor Growth and Invasiveness2.7. Quercetinś Role as an Anti-Inflammatory Agent; 2.8. Quercetinś Influence on p53; 2.9. Quercetinś Nontoxicity Against Normal Cells; 2.10. Quercetinś Action Against Chemical-Induced Tumor and Xenograft; 2.11. Synergism with Other Drugs; 2.12. Clinical Study; 3. Tryptanthrin; 3.1. Chemistry; 3.2. Source; 3.3. Medicinal Value; 3.4. Cytotoxic and Anticancer Properties of Tryptanthrin; 3.5. Structural Modification of Tryptanthrin for Increasing its Bioactivity 3.6. Tryptanthrin Prevents Development of Cancer by the Inhibition of Various Molecular Events3.6.1. Antioxidant Activity; 3.6.2. Anti-Inflammatory Activity; 3.7. Angiogenesis; 3.8. Toxicological Analysis; 4. Conclusion; Acknowledgement; References; Chapter Three: Potential Anticancer Properties and Mechanisms of Action of Withanolides; 1. Introduction; 2. Reactive Oxygen Species Signaling; 3. Cytoskeletal Organizing and Structural Proteins; 4. Proteasomal Inhibition; 5. Inhibition of Mitosis; 6. Transcription Factors; 7. Heat Shock Proteins; 8. Metabolic Enzymes; 9. Synergistic Action References |
Record Nr. | UNINA-9910828715703321 |
Waltham, MA : , : Elsevier Science, , 2015 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Neglected tropical diseases and phytochemicals in drug discovery / / edited by Chukwuebuka Egbuna, Muhammad Akram, Jonathan Chinenye Ifemeje |
Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] |
Descrizione fisica | 1 online resource (624 pages) |
Disciplina | 616.9883 |
Soggetto topico |
Tropical medicine
Phytochemicals - Therapeutic use |
Soggetto genere / forma | Electronic books. |
ISBN |
1-119-61715-4
1-119-61714-6 1-119-61711-1 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Preface -- Part I Introduction to Neglected Tropical Diseases -- Chapter 1 Epidemiology of Neglected Tropical Diseases -- List of Abbreviations -- 1.1 Introduction -- 1.2 Protozoan Infections -- 1.2.1 Human African Trypanosomiasis -- 1.2.2 Chagas Disease (American Trypanosomiasis) -- 1.2.3 Leishmaniasis -- 1.2.4 Amoebiasis -- 1.3 Helminth Infections -- 1.3.1 Soil-Transmitted Helminthiasis Infections -- 1.3.2 Schistosomiasis -- 1.3.3 Echinococcosis -- 1.3.4 Lymphatic Filariasis -- 1.3.5 Onchocerciasis ("River Blindness") -- 1.3.6 Foodborne Trematodiases -- 1.3.7 Dracunculiasis (Also Called Guinea Worm Disease) -- 1.4 Bacterial Infections -- 1.4.1 Yaws -- 1.4.2 Trachoma -- 1.4.3 Leprosy -- 1.4.4 Buruli Ulcer -- 1.5 Viral Infections -- 1.5.1 Rabies -- 1.5.2 Dengue -- 1.5.3 Chikungunya -- 1.6 Fungal and Ectoparasitic Infections -- 1.6.1 Chromoblastomycosis, Mycetoma/Eumycetoma, and Other Deep Mycoses -- 1.6.2 Scabies -- 1.6.3 Myiasis -- 1.7 Future Direction -- 1.8 Conclusion -- Acknowledgments -- References -- Chapter 2 Neglected Tropical Diseases, Phytochemicals, Protein Targets, and Mechanisms in Drug Discovery -- List of Abbreviations -- 2.1 Introduction -- 2.2 African Trypanosomiasis -- 2.2.1 Phytochemicals Against African Trypanosomiasis -- 2.3 Buruli Ulcer -- 2.3.1 Phytochemicals Against Buruli Ulcer -- 2.4 Chagas Disease -- 2.4.1 Phytochemicals Against Chagas Disease -- 2.5 Chikungunya -- 2.5.1 Phytochemicals Against Chikungunya -- 2.6 Dengue -- 2.6.1 Phytochemicals Against Dengue -- 2.7 Leishmaniasis -- 2.7.1 Phytochemicals Against Leishmaniasis -- 2.8 Leprosy -- 2.8.1 Indeterminate Leprosy -- 2.8.2 Phytochemicals Against Leprosy -- 2.9 Lymphatic Filariasis -- 2.9.1 Phytochemicals Against Lymphatic Filariasis -- 2.10 Mycetoma -- 2.10.1 Phytochemicals Against Mycetoma.
2.11 Onchocerciasis -- 2.11.1 Phytochemicals Against Onchocerciasis -- 2.12 Rabies -- 2.12.1 Phytochemicals Against Rabies -- 2.13 Scabies -- 2.13.1 Phytochemicals Against Scabies -- 2.14 Schistosomiasis -- 2.14.1 Phytochemicals Against Schistosomiasis -- 2.15 Conclusion -- References -- Chapter 3 Novel Bioactive Lead Compounds for Drug Discovery Against Neglected Tropical Diseases, Leishmaniasis, Lymphatic Filariasis, Trypanosomiasis (African Sleeping Sickness and Chagas Disease), and Schistosomiasis -- List of Abbreviations/Definitions -- 3.1 Introduction -- 3.2 Prevalence of Neglected Tropical Diseases -- 3.2.1 Leishmaniasis -- 3.2.2 Lymphatic Filariasis -- 3.2.3 Trypanosomiasis -- 3.2.3.1 African Trypanosomiasis (African Sleeping Sickness) -- 3.2.3.2 American Trypanosomiasis (Chagas Disease) -- 3.2.4 Schistosomiasis -- 3.3 Novel, Economical, and Efficacious Therapeutics from Medicinal Plants Against NTDs -- 3.3.1 Phytochemicals Effective Against Leishmania Parasite -- 3.3.2 Plants and Phytochemicals Effective Against Filarial Parasite -- 3.3.3 Plants and Phytochemicals Effective Against Trypanosomasis -- 3.3.4 Plants and Phytochemicals Effective Against Schistosomiasis -- 3.4 Future Prospects -- 3.5 Conclusion -- References -- Part II Protozoan Infections -- Chapter 4 Herbal, Nutritional, and Traditional Remedies for Giardiasis: Phytochemicals as Drug Candidates -- List of Abbreviations -- 4.1 Introduction -- 4.1.1 Epidemiology and Symptoms of Giardiasis -- 4.1.2 Life Cycle of G. duodenalis -- 4.1.3 Pathophysiology of Giardial Infection -- 4.1.4 Resistance to Allopathic Drug and Relevance of Herbal Medication -- 4.2 Plant-Based Dietary Supplements for Giardiasis Management -- 4.2.1 Oligosaccharide and Disaccharidase Supplementation -- 4.2.2 Dietary Fiber-Enriched Food -- 4.2.3 Agglutinin from Wheat -- 4.2.4 Vitamin and Mineral Supplements. 4.2.4.1 Vitamin A Supplementation -- 4.2.4.2 Compensation of Vitamin B12 -- 4.2.4.3 Zinc Status Management -- 4.2.5 Fermented Vegetables as Probiotic Source -- 4.2.6 Phenolic Compound Enriched Plant Food -- 4.3 Traditional Treatment of Giardiasis with Herbal Ethnomedicine -- 4.3.1 Hints of Antiprotozoal Medicines from Ancient Communities -- 4.3.2 Domestic Remedies and Alternative Medicine for Giardiasis -- 4.3.3 Applied Spectrum of Ethnopharmacology in Different Continents -- 4.3.3.1 Asian Medicinal Extracts -- 4.3.3.2 African Traditional Medicines -- 4.3.3.3 South American Ethnomedicine -- 4.4 Phytochemical Candidates for Advanced Giardicidal Drug Development -- 4.4.1 Terpenoids -- 4.4.2 Aromatic Ether -- 4.4.3 Alkaloids -- 4.4.4 Organo-sulfur Compounds -- 4.4.5 Lipids and Steroids -- 4.4.6 Phenolic Compounds -- 4.5 Future Prospects -- 4.5.1 Extension of Medicinal Compound Screening -- 4.5.2 Methodical Studies on Toxicology and Drug Adversity -- 4.5.3 Correlation of Herbal Drugs with Molecular Targets of Giardia -- 4.6 Summary, Prospects, and Conclusion -- References -- Chapter 5 Antiprotozoal Activity of Phytochemicals Against Entamoeba histolytica, the Causative Agent of Amoebiasis -- List of Abbreviations -- 5.1 Introduction -- 5.2 Life Cycle of Entamoeba histolytica -- 5.3 Diagnostic Techniques for Identification of E. histolytica -- 5.3.1 Intestinal Amoebiasis -- 5.3.1.1 Microscopy -- 5.3.1.2 Culture and Isoenzyme Analysis -- 5.3.1.3 Antigen Detection Test -- 5.3.1.4 Molecular-Based Test -- 5.3.1.5 Point-of-Care (POC) Test -- 5.4 Treatment of Amoebiasis -- 5.5 Alternative Treatment for Amoebiasis -- 5.6 Chemical Structure of Phytochemicals Effective Against E. histolytica -- 5.7 Possible Mechanisms of Phytochemicals as Antiamoebic -- 5.8 Future Projections -- 5.9 Conclusion -- References -- Chapter 6 Antileishmanial Potentials of Phytochemicals. 6.1 Introduction -- 6.2 Antileishmanial Activity of Propolis -- 6.2.1 Propolis from Turkey -- 6.2.2 Propolis from Brazil -- 6.2.3 Propolis from Portugal -- 6.2.4 Propolis from Cuba -- 6.2.5 Propolis from Ecuador -- 6.3 Antileishmanial Activity of Wild Mushrooms -- 6.4 Antileishmanial Activity of Medicinal Plants from Various Flora -- 6.4.1 Peruvian Flora -- 6.4.2 Ecuadorean Flora -- 6.4.3 Mexican Flora -- 6.4.4 Bolivian Flora -- 6.4.5 Iranian Flora -- 6.5 Antileishmanial Activity of Chemical Constituents -- 6.5.1 Alkaloids -- 6.5.2 Flavonoids -- 6.5.3 Terpenes -- 6.5.4 Glycoglycerolipids -- 6.5.5 Guttiferone A as a Lead Compound for Semisynthesis of Antileishmanial Molecules -- 6.6 Conclusion -- References -- Part III Helminth Infections -- Chapter 7 Prospects of Phytochemicals for the Treatment of Helminthiasis -- List of Abbreviations -- 7.1 Introduction -- 7.1.1 History -- 7.1.2 Prevalence -- 7.2 Molecular Characteristics of Soil-transmitted Helminthiasis -- 7.3 Clinical Features and Pathogenesis -- 7.4 Prevention -- 7.5 Treatment -- 7.6 Plants and Phytochemicals with Anthelmintic Activities -- 7.6.1 Modes of Action of Phytochemical Against the Soil-transmitted Helminthiasis -- 7.7 Scientific Reports of Medicinal Plants with Anthelmintic Properties -- 7.7.1 Adhatoda vasica -- 7.7.2 Allium sativum -- 7.7.3 Baliospermum montanum Muell -- 7.7.4 Butea monosperma -- 7.7.5 Calotropis procera -- 7.7.6 Carica papaya -- 7.7.7 Ficus benghalensis -- 7.7.8 Mimosa pudica -- 7.7.9 Punica granatum -- 7.7.10 Verbascum thapsus -- 7.7.11 Zingiber officinale -- 7.8 Future Prospects -- 7.9 Conclusion -- References -- Chapter 8 Efficacy of Phytochemicals of Medicinal Plants for the Treatment of Human Echinococcosis: Echinococcal Disease, Hydatidosis, or Hydatid Disease Drug Discovery -- List of Abbreviations -- 8.1 Introduction -- 8.2 Molecular Analysis. 8.3 Life Cycle of Echinococcosis -- 8.4 Previous Studies on the Positive Effects of Medicinal Plants and Phytochemicals -- 8.4.1 In vitro and in vivo Effect of Phytochemicals Against Echinococcus Infection -- 8.5 Synthetic Drugs Previously Used for Management of Echinococcosis Disease -- 8.6 Conclusion and Future Prospects -- References -- Chapter 9 Filaricidal Activity of Phytochemicals Against Lymphatic Filariasis -- List of Abbreviations -- 9.1 Introduction -- 9.2 Life Cycle of the Parasite -- 9.3 Synthetic Drugs Used for Treatment of Lymphatic Filariasis -- 9.4 Phytochemicals Used for the Treatment of Lymphatic Filariasis -- 9.4.1 Acacia auriculiformis -- 9.4.2 Aegle marmelos -- 9.4.3 Alnus nepalensis -- 9.4.4 Andrographis paniculata -- 9.4.5 Azadirachta indica -- 9.4.6 Bauhinia racemosa -- 9.4.7 Butea monosperma -- 9.4.8 Caesalpinia bonducella -- 9.4.9 Cardiospermum halicacabum -- 9.4.10 Centratherum anthelminticum -- 9.4.11 Excoecaria agallocha -- 9.4.12 Ficus racemosa -- 9.4.13 Glycyrrhiza glabra -- 9.4.14 Hibiscus sabdariffa -- 9.4.15 Lantana camara -- 9.4.16 Leucas cephalotes -- 9.4.17 Mallotus philippensis -- 9.4.18 Morinda citrifolia -- 9.4.19 Moringa oleifera -- 9.4.20 Plumbago indica -- 9.4.21 Pongamia pinnata -- 9.4.22 Psoralea corylifolia -- 9.4.23 Ricinus communis -- 9.4.24 Saxifraga stracheyion -- 9.4.25 Sphaeranthus indicus -- 9.4.26 Streblus asper -- 9.4.27 Trachyspermum ammi -- 9.4.28 Vitex negundo -- 9.4.29 Xylocarpus granatum -- 9.4.30 Zingiber officinale -- 9.5 Future Perspective -- 9.6 Conclusion -- References -- Chapter 10 Dracunculiasis (Guinea Worm Disease) and Phytochemicals in Drug Discovery -- List of Abbreviations -- 10.1 Introduction -- 10.2 Historical Insights of Dracunculiasis -- 10.3 Prevalence, Burden, and Distribution of Disease -- 10.4 Life Cycle, Pathogenesis, and Clinical Manifestations of Dracunculiasis. 10.5 Prevention and Eradication of Disease. |
Record Nr. | UNINA-9910555163203321 |
Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Neglected tropical diseases and phytochemicals in drug discovery / / edited by Chukwuebuka Egbuna, Muhammad Akram, Jonathan Chinenye Ifemeje |
Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] |
Descrizione fisica | 1 online resource (624 pages) |
Disciplina | 616.9883 |
Soggetto topico |
Tropical medicine
Phytochemicals - Therapeutic use |
ISBN |
1-119-61715-4
1-119-61714-6 1-119-61711-1 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Preface -- Part I Introduction to Neglected Tropical Diseases -- Chapter 1 Epidemiology of Neglected Tropical Diseases -- List of Abbreviations -- 1.1 Introduction -- 1.2 Protozoan Infections -- 1.2.1 Human African Trypanosomiasis -- 1.2.2 Chagas Disease (American Trypanosomiasis) -- 1.2.3 Leishmaniasis -- 1.2.4 Amoebiasis -- 1.3 Helminth Infections -- 1.3.1 Soil-Transmitted Helminthiasis Infections -- 1.3.2 Schistosomiasis -- 1.3.3 Echinococcosis -- 1.3.4 Lymphatic Filariasis -- 1.3.5 Onchocerciasis ("River Blindness") -- 1.3.6 Foodborne Trematodiases -- 1.3.7 Dracunculiasis (Also Called Guinea Worm Disease) -- 1.4 Bacterial Infections -- 1.4.1 Yaws -- 1.4.2 Trachoma -- 1.4.3 Leprosy -- 1.4.4 Buruli Ulcer -- 1.5 Viral Infections -- 1.5.1 Rabies -- 1.5.2 Dengue -- 1.5.3 Chikungunya -- 1.6 Fungal and Ectoparasitic Infections -- 1.6.1 Chromoblastomycosis, Mycetoma/Eumycetoma, and Other Deep Mycoses -- 1.6.2 Scabies -- 1.6.3 Myiasis -- 1.7 Future Direction -- 1.8 Conclusion -- Acknowledgments -- References -- Chapter 2 Neglected Tropical Diseases, Phytochemicals, Protein Targets, and Mechanisms in Drug Discovery -- List of Abbreviations -- 2.1 Introduction -- 2.2 African Trypanosomiasis -- 2.2.1 Phytochemicals Against African Trypanosomiasis -- 2.3 Buruli Ulcer -- 2.3.1 Phytochemicals Against Buruli Ulcer -- 2.4 Chagas Disease -- 2.4.1 Phytochemicals Against Chagas Disease -- 2.5 Chikungunya -- 2.5.1 Phytochemicals Against Chikungunya -- 2.6 Dengue -- 2.6.1 Phytochemicals Against Dengue -- 2.7 Leishmaniasis -- 2.7.1 Phytochemicals Against Leishmaniasis -- 2.8 Leprosy -- 2.8.1 Indeterminate Leprosy -- 2.8.2 Phytochemicals Against Leprosy -- 2.9 Lymphatic Filariasis -- 2.9.1 Phytochemicals Against Lymphatic Filariasis -- 2.10 Mycetoma -- 2.10.1 Phytochemicals Against Mycetoma.
2.11 Onchocerciasis -- 2.11.1 Phytochemicals Against Onchocerciasis -- 2.12 Rabies -- 2.12.1 Phytochemicals Against Rabies -- 2.13 Scabies -- 2.13.1 Phytochemicals Against Scabies -- 2.14 Schistosomiasis -- 2.14.1 Phytochemicals Against Schistosomiasis -- 2.15 Conclusion -- References -- Chapter 3 Novel Bioactive Lead Compounds for Drug Discovery Against Neglected Tropical Diseases, Leishmaniasis, Lymphatic Filariasis, Trypanosomiasis (African Sleeping Sickness and Chagas Disease), and Schistosomiasis -- List of Abbreviations/Definitions -- 3.1 Introduction -- 3.2 Prevalence of Neglected Tropical Diseases -- 3.2.1 Leishmaniasis -- 3.2.2 Lymphatic Filariasis -- 3.2.3 Trypanosomiasis -- 3.2.3.1 African Trypanosomiasis (African Sleeping Sickness) -- 3.2.3.2 American Trypanosomiasis (Chagas Disease) -- 3.2.4 Schistosomiasis -- 3.3 Novel, Economical, and Efficacious Therapeutics from Medicinal Plants Against NTDs -- 3.3.1 Phytochemicals Effective Against Leishmania Parasite -- 3.3.2 Plants and Phytochemicals Effective Against Filarial Parasite -- 3.3.3 Plants and Phytochemicals Effective Against Trypanosomasis -- 3.3.4 Plants and Phytochemicals Effective Against Schistosomiasis -- 3.4 Future Prospects -- 3.5 Conclusion -- References -- Part II Protozoan Infections -- Chapter 4 Herbal, Nutritional, and Traditional Remedies for Giardiasis: Phytochemicals as Drug Candidates -- List of Abbreviations -- 4.1 Introduction -- 4.1.1 Epidemiology and Symptoms of Giardiasis -- 4.1.2 Life Cycle of G. duodenalis -- 4.1.3 Pathophysiology of Giardial Infection -- 4.1.4 Resistance to Allopathic Drug and Relevance of Herbal Medication -- 4.2 Plant-Based Dietary Supplements for Giardiasis Management -- 4.2.1 Oligosaccharide and Disaccharidase Supplementation -- 4.2.2 Dietary Fiber-Enriched Food -- 4.2.3 Agglutinin from Wheat -- 4.2.4 Vitamin and Mineral Supplements. 4.2.4.1 Vitamin A Supplementation -- 4.2.4.2 Compensation of Vitamin B12 -- 4.2.4.3 Zinc Status Management -- 4.2.5 Fermented Vegetables as Probiotic Source -- 4.2.6 Phenolic Compound Enriched Plant Food -- 4.3 Traditional Treatment of Giardiasis with Herbal Ethnomedicine -- 4.3.1 Hints of Antiprotozoal Medicines from Ancient Communities -- 4.3.2 Domestic Remedies and Alternative Medicine for Giardiasis -- 4.3.3 Applied Spectrum of Ethnopharmacology in Different Continents -- 4.3.3.1 Asian Medicinal Extracts -- 4.3.3.2 African Traditional Medicines -- 4.3.3.3 South American Ethnomedicine -- 4.4 Phytochemical Candidates for Advanced Giardicidal Drug Development -- 4.4.1 Terpenoids -- 4.4.2 Aromatic Ether -- 4.4.3 Alkaloids -- 4.4.4 Organo-sulfur Compounds -- 4.4.5 Lipids and Steroids -- 4.4.6 Phenolic Compounds -- 4.5 Future Prospects -- 4.5.1 Extension of Medicinal Compound Screening -- 4.5.2 Methodical Studies on Toxicology and Drug Adversity -- 4.5.3 Correlation of Herbal Drugs with Molecular Targets of Giardia -- 4.6 Summary, Prospects, and Conclusion -- References -- Chapter 5 Antiprotozoal Activity of Phytochemicals Against Entamoeba histolytica, the Causative Agent of Amoebiasis -- List of Abbreviations -- 5.1 Introduction -- 5.2 Life Cycle of Entamoeba histolytica -- 5.3 Diagnostic Techniques for Identification of E. histolytica -- 5.3.1 Intestinal Amoebiasis -- 5.3.1.1 Microscopy -- 5.3.1.2 Culture and Isoenzyme Analysis -- 5.3.1.3 Antigen Detection Test -- 5.3.1.4 Molecular-Based Test -- 5.3.1.5 Point-of-Care (POC) Test -- 5.4 Treatment of Amoebiasis -- 5.5 Alternative Treatment for Amoebiasis -- 5.6 Chemical Structure of Phytochemicals Effective Against E. histolytica -- 5.7 Possible Mechanisms of Phytochemicals as Antiamoebic -- 5.8 Future Projections -- 5.9 Conclusion -- References -- Chapter 6 Antileishmanial Potentials of Phytochemicals. 6.1 Introduction -- 6.2 Antileishmanial Activity of Propolis -- 6.2.1 Propolis from Turkey -- 6.2.2 Propolis from Brazil -- 6.2.3 Propolis from Portugal -- 6.2.4 Propolis from Cuba -- 6.2.5 Propolis from Ecuador -- 6.3 Antileishmanial Activity of Wild Mushrooms -- 6.4 Antileishmanial Activity of Medicinal Plants from Various Flora -- 6.4.1 Peruvian Flora -- 6.4.2 Ecuadorean Flora -- 6.4.3 Mexican Flora -- 6.4.4 Bolivian Flora -- 6.4.5 Iranian Flora -- 6.5 Antileishmanial Activity of Chemical Constituents -- 6.5.1 Alkaloids -- 6.5.2 Flavonoids -- 6.5.3 Terpenes -- 6.5.4 Glycoglycerolipids -- 6.5.5 Guttiferone A as a Lead Compound for Semisynthesis of Antileishmanial Molecules -- 6.6 Conclusion -- References -- Part III Helminth Infections -- Chapter 7 Prospects of Phytochemicals for the Treatment of Helminthiasis -- List of Abbreviations -- 7.1 Introduction -- 7.1.1 History -- 7.1.2 Prevalence -- 7.2 Molecular Characteristics of Soil-transmitted Helminthiasis -- 7.3 Clinical Features and Pathogenesis -- 7.4 Prevention -- 7.5 Treatment -- 7.6 Plants and Phytochemicals with Anthelmintic Activities -- 7.6.1 Modes of Action of Phytochemical Against the Soil-transmitted Helminthiasis -- 7.7 Scientific Reports of Medicinal Plants with Anthelmintic Properties -- 7.7.1 Adhatoda vasica -- 7.7.2 Allium sativum -- 7.7.3 Baliospermum montanum Muell -- 7.7.4 Butea monosperma -- 7.7.5 Calotropis procera -- 7.7.6 Carica papaya -- 7.7.7 Ficus benghalensis -- 7.7.8 Mimosa pudica -- 7.7.9 Punica granatum -- 7.7.10 Verbascum thapsus -- 7.7.11 Zingiber officinale -- 7.8 Future Prospects -- 7.9 Conclusion -- References -- Chapter 8 Efficacy of Phytochemicals of Medicinal Plants for the Treatment of Human Echinococcosis: Echinococcal Disease, Hydatidosis, or Hydatid Disease Drug Discovery -- List of Abbreviations -- 8.1 Introduction -- 8.2 Molecular Analysis. 8.3 Life Cycle of Echinococcosis -- 8.4 Previous Studies on the Positive Effects of Medicinal Plants and Phytochemicals -- 8.4.1 In vitro and in vivo Effect of Phytochemicals Against Echinococcus Infection -- 8.5 Synthetic Drugs Previously Used for Management of Echinococcosis Disease -- 8.6 Conclusion and Future Prospects -- References -- Chapter 9 Filaricidal Activity of Phytochemicals Against Lymphatic Filariasis -- List of Abbreviations -- 9.1 Introduction -- 9.2 Life Cycle of the Parasite -- 9.3 Synthetic Drugs Used for Treatment of Lymphatic Filariasis -- 9.4 Phytochemicals Used for the Treatment of Lymphatic Filariasis -- 9.4.1 Acacia auriculiformis -- 9.4.2 Aegle marmelos -- 9.4.3 Alnus nepalensis -- 9.4.4 Andrographis paniculata -- 9.4.5 Azadirachta indica -- 9.4.6 Bauhinia racemosa -- 9.4.7 Butea monosperma -- 9.4.8 Caesalpinia bonducella -- 9.4.9 Cardiospermum halicacabum -- 9.4.10 Centratherum anthelminticum -- 9.4.11 Excoecaria agallocha -- 9.4.12 Ficus racemosa -- 9.4.13 Glycyrrhiza glabra -- 9.4.14 Hibiscus sabdariffa -- 9.4.15 Lantana camara -- 9.4.16 Leucas cephalotes -- 9.4.17 Mallotus philippensis -- 9.4.18 Morinda citrifolia -- 9.4.19 Moringa oleifera -- 9.4.20 Plumbago indica -- 9.4.21 Pongamia pinnata -- 9.4.22 Psoralea corylifolia -- 9.4.23 Ricinus communis -- 9.4.24 Saxifraga stracheyion -- 9.4.25 Sphaeranthus indicus -- 9.4.26 Streblus asper -- 9.4.27 Trachyspermum ammi -- 9.4.28 Vitex negundo -- 9.4.29 Xylocarpus granatum -- 9.4.30 Zingiber officinale -- 9.5 Future Perspective -- 9.6 Conclusion -- References -- Chapter 10 Dracunculiasis (Guinea Worm Disease) and Phytochemicals in Drug Discovery -- List of Abbreviations -- 10.1 Introduction -- 10.2 Historical Insights of Dracunculiasis -- 10.3 Prevalence, Burden, and Distribution of Disease -- 10.4 Life Cycle, Pathogenesis, and Clinical Manifestations of Dracunculiasis. 10.5 Prevention and Eradication of Disease. |
Record Nr. | UNINA-9910830428403321 |
Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Phytopharmaceuticals : potential therapeutic applications / / edited by Durgesh Nandini Chauhan and Kamal Shah |
Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley-Scrivener, , [2021] |
Descrizione fisica | 1 online resource (556 pages) |
Disciplina | 615.321 |
Soggetto topico | Phytochemicals - Therapeutic use |
Soggetto genere / forma | Electronic books. |
ISBN |
1-5231-4371-1
1-119-68197-9 1-119-68205-3 1-119-68207-X |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910555099503321 |
Hoboken, New Jersey : , : Wiley-Scrivener, , [2021] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Phytopharmaceuticals : potential therapeutic applications / / edited by Durgesh Nandini Chauhan and Kamal Shah |
Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley-Scrivener, , [2021] |
Descrizione fisica | 1 online resource (556 pages) |
Disciplina | 615.321 |
Soggetto topico | Phytochemicals - Therapeutic use |
ISBN |
1-5231-4371-1
1-119-68197-9 1-119-68205-3 1-119-68207-X |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910830477503321 |
Hoboken, New Jersey : , : Wiley-Scrivener, , [2021] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|